Mechanisms of Resistance to BCR-ABL Kinase Inhibitors

Authors

  • Joana Diamond Laboratório de Hemato-Oncologia. Unidade de Biologia Molecular. Instituto Português de Oncologia Francisco Gentil. Lisboa. Portugal.
  • Maria Gomes da Silva Serviço de Hematologia. Instituto Português de Oncologia Francisco Gentil. Faculdade de Ciências Médicas da Universidade Nova de Lisboa. Lisboa. Portugal.

DOI:

https://doi.org/10.20344/amp.4812

Abstract

Since the introduction of imatinib mesylate for the treatment of chronic myeloid leukaemia, impressive clinical responses were observed in the majority of patients in chronic phase. However, not all patients experience an optimal response to imatinib mesylate or even to the more potent, second generation tyrosine kinase inhibitors. Furthermore, responses are not sustained in a number of patients, and it is yet unclear whether the inhibitors can be safely discontinued in patients who achieve long-term remission. The emergence of resistance to second generation tyrosine kinase inhibitors has become a significant problem that led to extensive studies on the causal mechanisms. This review will describe our current state of knowledge on why and how chronic myeloid leukaemia cells can develop resistance to second generation tyrosine kinase inhibitors.

Downloads

Download data is not yet available.

Author Biographies

Joana Diamond, Laboratório de Hemato-Oncologia. Unidade de Biologia Molecular. Instituto Português de Oncologia Francisco Gentil. Lisboa. Portugal.

Maria Gomes da Silva, Serviço de Hematologia. Instituto Português de Oncologia Francisco Gentil. Faculdade de Ciências Médicas da Universidade Nova de Lisboa. Lisboa. Portugal.

Published

2013-08-30

How to Cite

1.
Diamond J, da Silva MG. Mechanisms of Resistance to BCR-ABL Kinase Inhibitors. Acta Med Port [Internet]. 2013 Aug. 30 [cited 2024 Mar. 29];26(4):402-8. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/4812

Issue

Section

Review Articles